Comparative Pharmacology
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus MPI DTPA KIT CHELATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus MPI DTPA KIT CHELATE.
IODOHIPPURATE SODIUM I 131 vs MPI DTPA KIT - CHELATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical